This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Amryt Pharma Gestione

Criteri Gestione verificati 3/4

Amryt Pharma Il CEO è Joe Wiley, nominato in Jan2015, e ha un mandato di 8.25 anni. la retribuzione annua totale è $ 1.72M, composta da 43.4% di stipendio e 56.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.1% delle azioni della società, per un valore di $ 10.36M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.3 anni e 3.6 anni.

Informazioni chiave

Joe Wiley

Amministratore delegato

US$1.7m

Compenso totale

Percentuale dello stipendio del CEO	43.43%
Mandato del CEO	8.3yrs
Proprietà del CEO	1.1%
Durata media del management	3.3yrs
Durata media del Consiglio di amministrazione	3.6yrs

Aggiornamenti recenti sulla gestione

Nessun aggiornamento

Recent updates

Seeking Alpha • Oct 18

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

A committee of the European Medicines Agency (EMA) recommended that the orphan disease designation to Amryt's (NASDAQ:AMYT) Mycapssa to treat acromegaly in the EU is maintained. Acromegaly is a disorder characterized by the pituitary gland producing too much growth hormone during adulthood. The bones in the hands, feet and face become bigger. The EMA's Committee for Orphan Medicinal Products (COMP) adopted the positive opinion. "The COMP recommendation to maintain the orphan disease designation for Mycapssa confirms the significant benefit of Mycapssa over the currently available injectable forms of somatostatin analogues, which represents a significant development for acromegaly sufferers in Europe," said Amryt CEO Joe Wiley. In September, EMA's Committee for Medicinal Products for Human Use (CHMP) had recommended the approval of Mycapssa as a maintenance therapy for certain patients with acromegaly. The orphan drug status in the EU provides for incentives, including 10 years' of market exclusivity for the drug, if approved.

Seeking Alpha • Sep 16

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

A committee of the European Medicines Agency (EMA) recommended the approval of Amryt's (NASDAQ:AMYT) Mycapssa (octreotide capsules) in the EU as a maintenance therapy of acromegaly in patients who have responded to and tolerated treatment with octreotide or lanreotide. Acromegaly is a disorder characterized by the pituitary gland producing too much growth hormone during adulthood. The bones in the hands, feet and face become bigger. The decision of the EMA's Committee for Medicinal Products for Human Use (CHMP) was backed by data from a phase 3 trial called MPOWERED. The European Commission (EC), which generally follows the opinion of the CHMP, will now decide on the drug's approval. The EC decision is expected within within 67 days, the company said in a Sept. 16 press release. "The CHMP recommendation for approval of Mycapssa is a very significant development for acromegaly sufferers in Europe and Mycapssa would be the first and only oral somatostatin analog approved in the EU," said Amryt CEO Joe Wiley.

Seeking Alpha • Sep 08

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Irish commercial-stage biopharma Amryt (NASDAQ:AMYT) on Thursday said UK's drug regulator had approved its Filsuvez gel to treat wounds associated with genetic skin disorder epidermolysis bullosa (EB). U.S.-listed shares of AMYT were 3.5% higher at $7.93 in premarket trading. The UK's Medical Healthcare & Products Regulatory Agency granted a marketing authorization and an orphan drug designation to Filsuvez for the treatment of partial thickness wounds associated with dystrophic and junctional EB in patients 6 months and older, AMYT said in a statement. "We look forward to continuing our discussions with the reimbursement agencies across the UK and European Union to begin delivering Filsuvez to treat patients as soon as possible...," AMYT CEO Joe Wiley said. The nod from the British regulator comes after the European Commission approved Filsuvez in Aug. The U.S. FDA rejected the company's approval application for Filsuvez in Feb., with Amryt (AMYT) later saying it would appeal the so-called complete response letter.

Seeking Alpha • Jul 14

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Amryt's (NASDAQ:AMYT) Mycapssa to treat carcinoid syndrome (CS). CS occurs when a rare cancerous tumor called carcinoid tumor releases certain chemicals in the blood, causing several symptoms. According to the company CS is the most common functional syndrome associated with neuroendocrine tumours (NETs). Mycapssa (oral octreotide) is approved by the FDA as a long-term maintenance therapy for certain patients with acromegaly, a hormonal disorder which occurs when the pituitary gland produces too much growth hormone during adulthood. Amryt noted that its TPE platform enables the oral delivery of the octreotide molecule which is otherwise delivered as an injectable. The FDA grants orphan drug status to therapies that treat or prevent rare diseases that affect fewer than 200K people in the U.S. The designation provides certain incentives, including seven years of market exclusivity, if approved. AMYT +11.19% to $8.25 premarket July 14.

Seeking Alpha • Jun 23

Amryt's Filsuvez gets approval in EU to treat rare skin disorder

The European Commission (EC) approved Amryt's (NASDAQ:AMYT) Filsuvez to treat partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in patients 6 months and older. EB is a rare disease in which the skin becomes fragile and can tear or blister from minor injury/rubbing. Filsuvez will be the first and only approved therapy for patients EB, the Dublin-based company said in a June 23 press release. The approval was backed by data from a phase 3 trial called EASE which included 58 sites in 28 countries. The company noted that authorization of Filsuvez® in the EU provides a regulatory core dossier which may form the basis for future regulatory submissions in LATAM and the Middle East. A day ago, Krystal Biotech (KRYS) filed for U.S. approval of its topical gene therapy B-VEC to treat patients with dystrophic EB.

Seeking Alpha • Dec 09

Amryt Pharma: Advancing Novel Treatments For Rare And Debilitating Conditions

Amryt Pharma is developing and delivering innovative medicines for rare and debilitating conditions. The Company has acquired three companies since formation, and has commercialized three medicines. The Company also has a significant development pipeline.

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Joe Wiley rispetto agli utili di Amryt Pharma?
Data	Compenso totale	Stipendio	Utili della società
Sep 30 2022	n/a	n/a	-US$790k
Jun 30 2022	n/a	n/a	US$3m
Mar 31 2022	n/a	n/a	US$3m
Dec 31 2021	US$2m	US$747k	US$1m
Sep 30 2021	n/a	n/a	-US$88m
Jun 30 2021	n/a	n/a	-US$81m
Mar 31 2021	n/a	n/a	-US$92m
Dec 31 2020	US$2m	US$727k	-US$105m
Sep 30 2020	n/a	n/a	-US$87m
Jun 30 2020	n/a	n/a	-US$92m
Mar 31 2020	n/a	n/a	-US$87m
Dec 31 2019	US$1m	US$588k	-US$63m

Compensazione vs Mercato: La retribuzione totale di Joe ($USD 1.72M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.69M ).

Compensazione vs guadagni: La retribuzione di Joe è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Joe Wiley (51 yo)

8.3yrs

Mandato

US$1,720,000

Compensazione

Dr. Joseph A. Wiley, also known as Joe, M.D. was the Founder of Amryt Pharma plc and serves as its Chief Executive Officer since 2015. He has been a Director at Amryt Pharma plc since April 19, 2016. Dr. W...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Joseph Wiley	CEO & Director	8.3yrs	US$1.72m	1.1% $ 10.4m
Rory Nealon	CFO, COO & Company Secretary	8.3yrs	US$939.00k	0.51% $ 4.8m
Elizabeth Jobes	Chief Compliance Officer	2.3yrs	Nessun dato	Nessun dato
John McEvoy	General Counsel	5.6yrs	Nessun dato	Nessun dato
Stephen Joyce	Head of Marketing & Head of APAC	4.3yrs	Nessun dato	Nessun dato
Julie Eastwood	Head of Human Resources	no data	Nessun dato	Nessun dato
Helen Phillips	Head of Medical Affairs	no data	Nessun dato	Nessun dato
Sheila Frame	President of Americas	2yrs	Nessun dato	Nessun dato
Tracy Cunningham	Chief Medical Officer	less than a year	Nessun dato	Nessun dato
Jordi Casals	President of EMEA Region	less than a year	Nessun dato	Nessun dato

3.3yrs

Durata media

54.5yo

Età media

Gestione esperta: Il team dirigenziale di AMYT è considerato esperto (durata media dell'incarico 3.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Joseph Wiley	CEO & Director	7yrs	US$1.72m	1.1% $ 10.4m
Stephen Wills	Independent Non-Executive Director	3.6yrs	US$88.00k	0.023% $ 220.5k
Alain Munoz	Independent Non-Executive Director	3.6yrs	US$58.00k	0.0070% $ 66.1k
Patrick V. J. Vink	Independent Non-Executive Director	3.6yrs	US$60.00k	0.0078% $ 73.5k
Donald Stern	Independent Non-Executive Director	3.6yrs	US$80.00k	0% $ 0
Raymond Stafford	Independent Non-Executive Chairman of the Board	7yrs	US$88.00k	0.61% $ 5.8m
Roni Mamluk	Independent Non-Executive Director	1.7yrs	US$20.00k	0% $ 0
George Hampton	Independent Non-Executive Director	3.6yrs	US$65.00k	0.031% $ 294.0k
Raj Kannan	Independent Non-Executive Director	1.7yrs	US$20.00k	0% $ 0

3.6yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AMYT sono considerati esperti (durata media dell'incarico 3.6 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2023/04/14 18:17
Prezzo dell'azione a fine giornata	2023/04/11 00:00
Utili	2022/09/30
Utili annuali	2021/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Amryt Pharma plc è coperta da 8 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Michelle Gilson	Canaccord Genuity
Brandon Folkes	Cantor Fitzgerald & Co.
Andrew Young	Davy